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We aimed to assess the efﬁcacy of vinorelbine plus granulocyte colonyestimulating factor (G-CSF) for chemo-
mobilization of CD34þ hematopoietic progenitor cells (HPC) in patients with multiple myeloma and to
identify adverse risk factors for successful mobilization. Vinorelbine 35 mg/m2 was administered intrave-
nously on day 1 in an outpatient setting. Filgrastim 5 mg/kg body weight (BW) was given twice daily
subcutaneously from day 4 until the end of the collection procedure. Leukapheresis was scheduled to start on
day 8 and be performed for a maximum of 3 consecutive days until at least 4  106 CD34þ cells per kg BW
were collected. Overall, 223 patients were mobilized and 221 (99%) patients proceeded to leukapheresis.
Three (1.5%) patients required an unscheduled hospitalization after chemo-mobilization because of
neutropenic fever and renal failure (n ¼ 1), severe bone pain (n ¼ 1), and abdominal pain with constipation
(n ¼ 1). In 211 (95%) patients, the leukaphereses were started as planned at day 8, whereas in 8 (3%) patients
the procedure was postponed to day 9 and in 2 (1%) patients to day 10. In the great majority of patients (77%),
the predeﬁned amount of HPC could be collected with 1 leukapheresis. Forty-four (20%) patients needed a
second leukapheresis, whereas only 6 (3%) patients required a third leukapheresis procedure. The median
number of CD34þ cells collected was 6.56  106 (range, .18 to 25.9  106) per kg BW at the ﬁrst day of
leukapheresis and 7.65  106 (range, .18 to 25.9  106) per kg BW in total. HPC collection was successful in 212
(95%) patients after a maximum of 3 leukaphereses. Patient age (P ¼ .02) and prior exposition to lenalidomide
(P < .001) were independent risk factors for a lower HPC amount collected in multiple regression analysis.
Vinorelbine plus G-CSF enables a very reliable prediction of the timing of leukapheresis and results in
successful HPC collection in 95% of the patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous stem cell transplantation (ASCT) after
high-dose melphalan improves the quality of response and
the survival of patients with multiple myeloma. It is an
established component in the ﬁrst-line treatment strategy
for patients capable of undergoing dose-intense chemo-
therapy [1-4].edgments on page 79.
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ty for Blood and Marrow Transplantation.Granulocyte colonyestimulating factor (G-CSF), alone or
combinedwith chemotherapy, is commonly used tomobilize
CD34þ hematopoietic progenitor cells (HPC) before patients
can proceed to high-dose treatment (HDT) [5-7]. The
chemotherapy regimen most frequently used for chemo-
mobilization is cyclophosphamide at low, intermediate, or
high doses of 1500 to 7000 mg/m2, followed by daily G-CSF
application until HPC collection [8-14]. By using additional
daily subcutaneous G-CSF administration, peak levels of HPC
can be variablymobilizedwith this regimenwithin the next 3
weeks, making repeated measurements of white blood cells
(WBC) or CD34þ cell counts in the peripheral blood necessary
to determine the optimal time for leukapheresis. The
P. Samaras et al. / Biol Blood Marrow Transplant 21 (2015) 74e80 75reported successful mobilization rates of about 82% to 94%
with this regimen in myeloma patients are thus achieved
with the drawbacks of low predictability of the optimal time
for HPC collection and possible complications of the cytotoxic
agent, such as febrile neutropenia, renal failure, or hemor-
rhagic cystitis [10,15-17]. In addition, cyclophosphamide is
often administered on an inpatient basis because of the need
for adequate hydration and monitoring of the patient, which
compromises patient comfort and increases treatment costs.
Cyclophosphamide is also known to be mutagenic and to
induce myelodysplasia or leukemia after a latency of a few
years [18]. Simpler, less toxic, and more predictable mobili-
zation regimens are warranted. Recently, the competitive
chemokine receptor 4eantagonist plerixafor has been shown
to be a good agent for HPCmobilizationwhen combinedwith
G-CSF. Accordingly, this regimen is increasingly being used
for upfront HPC mobilization, but it comes at high costs and
many transplantation centers consider it, therefore, primar-
ily for mobilization-refractory patients [19-23].
Vinorelbine is a semisynthetic vinca-alcaloid commonly
used for the treatment of breast cancer and nonesmall cell
lung carcinoma. A few years ago, its mobilizing potential
when combined with G-CSF was shown in 2 pilot studies in
patients with multiple myeloma and lymphoma [24,25].
Here, we report the long-term results of this regimen for
CD34þ HPC mobilization and the transplantation outcome
achieved with these leukapheresis products in patients with
multiple myeloma. We also assessed the impact of various
factors on the collection outcome with a special emphasis on
pretreatment with new immunomodulatory drugs.
PATIENTS AND METHODS
Study Design
The charts of all patients with multiple myeloma who underwent HPC
mobilization with vinorelbine and G-CSF at the transplantation center in
Zurich were retrospectively analyzed. The analysis was approved by the
local ethics committee.
Patients
Patients with multiple myelomawho underwent HPC mobilizationwith
vinorelbine and G-CSF from January 2004 to June 2013 were included in the
analysis. Patients mobilized with other regimens or upfront plerixafor were
excluded from this analysis. Cut-off for data acquisition was June 30, 2013.
We documented relevant patient characteristics before mobilization, all
previous chemotherapy drugs applied, and the duration of the respective
treatment lines. In addition, the number of leukaphereses, the CD34þ HPC
and WBC counts in the leukapheresis product, the WBC and thrombocyte
counts in the peripheral blood, and clinical data of the subsequent ﬁrst ASCT
in patients who underwent transplantation were recorded. In addition, we
assessed toxicity data as recorded in the patient records.
HPC Mobilization
Vinorelbine was applied at a dose of 35 mg/m2 as an intravenous bolus
infusion on day 1. The total dose was capped at a maximum of 60 mg. Fil-
grastim (Neupogen, Amgen, Thousand Oaks, CA or Zarzio, Sandoz, Holz-
kirchen, Germany) at a dose of 5 mg/kg of body weight (BW) was given twice
daily (10 mg/kg/day in total), subcutaneously from day 4 until the end of HPC
collection. Leukaphereses (COBE Spectra or Spectra Optia Apheresis System,
Terumo BCT, Lakewood, CO) started on day 8 andwere repeated daily until at
least 4  106 CD34þ HPC per kilogram of BW was collected, which was
deemed sufﬁcient for at least 2 ASCT. The common threshold for performing
the leukapheresiswas anabsoluteneutrophil count (ANC)of 1.0109/L in the
peripheral blood at day 8; otherwise, the procedure was postponed. Moni-
toring of CD34þ cells in the peripheral blood was not carried out routinely.
Theﬁrst apheresiswas performed by processing 3 to 4 times the donor’s total
blood volume by continuous ﬂow using peripheral or central venous access.
The maximum total volume processed did not exceed 20 liters. If a second
apheresis was necessary, the amount of the donor’s blood volume being
processedwas adjusted according to the results of the CD34þ cell count of the
previousday. If the target amountof 4106CD34þperkgBWwasnot reached
after a maximum of 3 leukaphereses, collections were stopped and the pa-
tient considered as having a mobilization failure. HPC viability was assessedwith the trypan blue dye exclusion technique. Finally, the collectedHPCwere
processed with the addition of dimethylsulfoxide at a concentration of 10%,
frozen in a controlled rate freezer, and cryopreserved in liquid-phase nitro-
gen. The products were thawed immediately before transplantation.
HDT and ASCT
Patients who proceeded to HDT after successful HPC collection received
melphalan 200 mg/m2 as a single infusion on day -2 or split in to 2 doses on
days -3 and -2 with subsequent ASCT of at least 2  106 CD34þ HPC per kg
BW at day 0. Patients over 65 years, with a reduced performance score or
comorbidities, such as renal or cardiac insufﬁciency, received a reduced dose
of 140 mg/m2 melphalan. Filgrastim was administered daily, starting on
day þ5, or pegﬁlgrastim (Neulasta, Amgen, Thousand Oaks, CA) was
administered on day þ1 as single injection to reduce the time to neutrophil
engraftment. Results from this experience have been reported previously
[26]. Engraftment was deﬁned as ANC increase  0.5  109/L over 3
consecutive days.
Statistical Analysis
Continuous variables are presented as median with range, and categor-
ical data as counts with percentages. Outcome parameters were the amount
of CD34þ HPC collected at the ﬁrst leukapheresis day and in total and the
number of leukaphereses performed. Univariate analyses for successful
collectionwere performed using theMann-Whitney test and Spearman rank
correlations, as appropriate. Exploratory variables assessed were pretreat-
ment regimens, especially lenalidomide and thalidomide-containing
chemotherapy; age; gender; previous irradiation; number of previous
treatment lines; and the overall duration of pretreatment. Variables with P
values < .10 in univariate analysis were entered into multiple linear regres-
sion models. Dependent variables were appropriately transformed to obtain
normally distributed residuals. Normal distributionwas assessed graphically.
Two-sided P values < .05 were considered statistically signiﬁcant. All
analyses were performed with IBM SPSS Statistics, Version 21.0 (IBM Corp,
Armonk, NY).
RESULTS
Patient Demographics
Between January 2004 and June 2013, a total of 223 pa-
tients with multiple myeloma underwent HPC mobilization
with vinorelbine plus G-CSF. Patient characteristics are
shown in Table 1.
HPC Collection
Overall, 221 (99%) patients could complete leukaphereses
after vinorelbine and G-CSF administration. One patient with
multiple lines of therapies reached only a maximum of 5
CD34þ cells per microliter in the peripheral blood and did
not proceed to leukapheresis. A second patient could not
undergo leukapheresis because of neutropenic fever with
renal impairment after administration of vinorelbine
requiring hospitalization and antibiotic treatment. In 211
(95%) patients, leukaphereses started as planned at day 8,
whereas in 8 (3%) patients, the procedure had to be post-
poned to day 9 and in 2 (1%) patients, to day 10. The reasons
for delaying the start of HPC collections were ANC counts <
1.0  109/L in the peripheral blood (n ¼ 3), ANC counts >
1.0  109/L but inadequate increase as decided by the
responsible transplantation physician (n ¼ 3), CD34þ HPC
counts< 10/mL in the peripheral blood (n¼ 1), termination of
the procedure because of technical reasons of the apheresis
system (n ¼ 1), no timely availability of a central venous
access line (n ¼ 1), and incorrect planning (n ¼ 1). In 171
(77%) patients, only 1 leukapheresis was performed. Forty-
four (20%) patients needed a second leukapheresis,
whereas 6 (3%) patients also received a third procedure. The
median number of CD34þ cells collected was 6.56  106
(range, .18 to 25.9  106) per kilogram BW on the ﬁrst day of
leukapheresis and 7.65  106 (range, .18 to 25.9  106) per
kilogram BW in total. The correspondingmedianWBC counts
in the peripheral blood at the ﬁrst day of apheresis were
Table 1
Patient Characteristics
Parameter N ¼ 223
Patient age, yr 58 (29-75)
BMI before ASCT, kg/m2 25.2 (16.8-40.6)
Male gender 134 (60)
Diagnosis
Multiple myeloma 220 (98.5)
Amyloidosis 3 (1.5)
Number of previous treatment lines
0 2 (1)
1 168 (75)
2 37 (17)
3 9 (4)
4 or more 7 (3)
First-line induction treatment chosen
Thalidomide-dexamethasone 41 (18)
Bortezomib-dexamethasone 60 (27)
Bortezomib-cyclophosphamide-dexamethasone 50 (22.5)
Bortezomib-thalidomide-dexamethasone 10 (4.5)
Lenalidomide-dexamethasone 12 (5)
Dexamethasone single agent 4 (2)
VAD 35 (16)
Other regimen 9 (4)
None 2 (1)
Previous irradiation
Yes 18 (8)
No 203 (91)
Data missing 2 (1)
Previous ASCT
Yes 2 (1)
No 221 (99)
BMI indicates body mass index; VAD, vincristine, doxorubicin, and dexa-
methasone.
Data are expressed as median (range) or n (%).
Table 3
Transplantation Outcome
Parameter n ¼ 208
Time from leukapheresis to ﬁrst HPC retransfusion, d 16 (4-1086)
Retransfused CD34þ HPC, 106/kg BW 3.62 (1.94-13)
Length of hospitalization (d from HPC retransfusion) 17 (11-47)
Time to engraftment, d 9 (5-24)
Duration of grade 4 neutropenia, d 5 (3-19)
Duration of grade 4 thrombocytopenia, d 4 (0-15)
Patients receiving RBC transfusions
Yes 51 (24.5)
No 139 (67)
Data missing 18 (8.5)
RBC units transfused per patient 0 (0-10)
Patients receiving platelet transfusions
Yes 153 (74)
No 38 (18)
Data missing 17 (8)
Platelet units transfused per patient 1 (0-10)
Treatment-related mortality 2 (1)
Data are expressed as median (range) or n (%).
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sponding median thrombocyte counts were 224  109/L
(range, 35 to 610  109/L). The median cell viability of the
HPC collected at the ﬁrst day was 96.6% (range, 50.3% to
99.4%). Overall, in 212 of 223 (95%) patients, mobilization
was successful with a maximum of 3 leukaphereses per-
formed. Mobilization failure occurred in 11 (5%) patients. In 3
of these patients, the failed HPC collection on the ﬁrst day
could be salvaged during the same mobilization attempt by
additional administration of plerixafor before the second day
of leukapheresis. Among the remaining 8 patients, 3 under-
went a second mobilization procedure. Two patients
received the same chemo-mobilizationwith vinorelbine plus
G-CSF and were mobilized successfully, and 1 patient
received cyclophosphamide plus G-CSF without success.
Overall, 6 (2.5%) patients could never be mobilized. The de-
tails of the HPC mobilization procedure are listed as Table 2.Table 2
Mobilization Data
Parameter Numbers
G-CSF dose per day, mg 780 (600-1260)
Interval mobilization to ﬁrst leukapheresis, d 7 (7-9)
No. of leukaphereses needed 1 (1-3)
WBC counts in peripheral blood at ﬁrst
leukapheresis day,  109/L
18.6 (1.8-59.4)
Thrombocyte counts in peripheral blood at
ﬁrst leukapheresis day,  109/L
224 (35-610)
Collected CD34þ HPC total, 106/kg BW 7.65 (.18-25.9)
Collected CD34þ HPC after ﬁrst
leukapheresis, 106/kg BW
6.56 (.18-25.9)
Cell viability from ﬁrst leukapheresis, % 96.6 (50.3-99.4)
Cell viability from second leukapheresis, % 96.7 (90-99.1)
Cell viability from third leukapheresis, % 95.1 (91.3-97.9)
Data are expressed as median (range).Transplantation Period
Overall, 208 (93.5%) patients underwent the ﬁrst ASCT at
a median of 16 days (range, 4 to 1086 days) after HPC
collection. Eighty-ﬁve percent of the patients received their
HPC within 50 days after collection. All patients experienced
grade 4 neutropenia after melphalan conditioning but ach-
ieved a stable engraftment after transfusion of a median of
3.62  106 (range, 1.94 to 13.0  106) CD34þ HPC per kilo-
gram BW. The median duration of grade 4 neutropenia and
the median time to engraftment from the day of HPC rein-
fusion were 5 days (range, 3 to 19 days) and 9 days (range, 5
to 24 days), respectively. The median duration of grade 4
thrombocytopenia was 4 days (range, 0 to 15 days). The
median length of hospital stay from the day of HPC reinfu-
sion was 17 days (range, 11 to 47). The majority of patients
required no red blood cell transfusions (range, 0 to 10 units)
and only a median of 1 platelet unit (range, 0 to 10 units)
during their hospital stay. Two (1%) patients died within 100
days after ASCT, 1 patient because of early myeloma pro-
gression and 1 patient died after prolonged septic compli-
cations. The results of the transplantation phase are shown
as Table 3.
Risk Factors for HPC Mobilization
The amounts of CD34þ HPC collected after the ﬁrst leu-
kapheresis and also after a maximum of 3 leukaphereses
were markedly lower in patients who had received lenali-
domide in previous lines of chemotherapy compared with
patients who had not received lenalidomide pretreatment. In
addition, thalidomide pretreatment resulted also in lower
amounts of CD34þ HPC collected but to a lesser extent
compared with lenalidomide (Figure 1). The median number
of HPC collected after the ﬁrst leukapheresis in lenalidomide
pretreated patients was 3.63  106 per kg BW (range, .56 to
15.5106/kg BW; P< .001) and 5.26 106/kg BW (range, .64
to 15.5  106/kg BW; P < .001) in total, respectively. Patients
had received lenalidomide within their respective pretreat-
ment regimens for a median of 4 months (range, 2 to 8
months). For thalidomide-pretreated patients, the corre-
sponding ﬁgures were 5.57 106/kg BW (range, .45 to 18.3
106/kg BW; P ¼ .001) after the ﬁrst leukapheresis and 6.54 
106/kg BW (range, 4.01 to 18.3106/kg BW; P¼ .006) in total.
The same adverse impact of lenalidomide and thalidomide
was seen if only patients with 1 previous treatment linewere
analyzed (data not shown).
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Figure 1. Number of CD34þ HPC collected at the ﬁrst leukapheresis day (A) and in total (B), stratiﬁed by the use of lenalidomide or thalidomide pretreatment. The
continuous line at 4  106/kg depicts the minimal aspired amount of CD34þ HPC. P values from Mann-Whitney U test.
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thalidomide was a negative factor for a sufﬁcient amount of
CD34þ HPC collected after the ﬁrst leukapheresis, and lenali-
domide was also a signiﬁcant negative factor for an overall
sufﬁcient CD34þ HPC collection. Patient age, the duration of
pretreatment, and the number of treatment lines were addi-
tional adverse risk factors for CD34þ HPC collection with only
1 leukapheresis and also for the overall collection success. Inmultivariable models, the administration of lenalidomide or
thalidomide before HPC mobilization and patient age
remained independent risk factors negatively affecting the
HPC collection results after the ﬁrst leukapheresis (adjusted R-
square: .14). Regarding the overall HPC collection, only the
administration of lenalidomide before HPC mobilization and
patient age remained independent risk factors with an
adjusted R-square of the ﬁnal model of .11 (Tables 4 and 5).
Table 4
Risk Factors for CD34þ HPC Collection at the First Leukapheresis Day
Variable Univariate Analysis Multiple Regression
Numbers, %/Median
(range)
Median (range) HPC,  106/kg Correlation
Coefﬁcient
P Value Standardized
Regression
Coefﬁcient
Adjusted
P Value
Lenalidomide-containing pretreatment 30/222 (13.5) 3.6 (.6-15.5) versus 8.9 (.2-25.9) - <.001 .31 <.001
Thalidomide-containing pretreatment 53/222 (23.9) 5.6 (.5-18.3) versus 8.9 (.2-25.9) - .017 .16 .03
Age 58.1 (28.8-75.1) - .15 .022 .14 .025
Male gender 134/223 (60.1) 7.4 (.2-25.9) versus 6.1 (.4-23.8) - .61 - -
Previous irradiation 18/221 (8) 4.5 (.6-18.6) versus 7.3 (.2-25.9) - .19 - -
Duration of pretreatment, mo 4 (1-16) - .25 <.001 .14 .09
No. of drugs 3 (0-9) - .004 .95 - -
No. of lines 1 (0-6) - .21 .002 .05 .59
Univariate and multiple regression analyses. Correlations coefﬁcient depicted for continuous variables, and median (range) of collected HPC depicted for
nominal variables together with the corresponding median (range) of the comparator groups (lenalidomide-containing versus no-lenalidomide/no-thalido-
mideecontaining treatment; thalidomide-containing versus no-lenalidomide/no-thalidomideecontaining treatment; male gender versus female gender;
previous irradiation versus no previous irradiation). P-values < .05 were considered statistically signiﬁcant (depicted in bold characters).
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Adverse events were infrequent and well manageable in
the majority of cases. The event most frequently recorded
was bone pain during G-CSF administration (n ¼ 100, 45%).
Patients received analgesic therapy as appropriate, and the
pain resolved shortly after cessation of G-CSF. Twenty-eight
(13%) patients reported abdominal discomfort, mostly pain
and constipation after vinorelbine administration. Two (1%)
patients reported mild paresthesias and tingling of their feet
and hands after vinorelbine, which was not interfering with
their daily living. Nine patients (4%) reported pre-existing
neuropathy because of their previous neurotoxic induction
treatment; seven (3%) of these patients reported no change
in severity of the neuropathy after vinorelbine administra-
tion, whereas in 2 (1%) patients, an increase in discomfort
was recorded necessitating an adaptation of their daily
pregabalin dose. Nine (4%) patients reported ﬂu-like symp-
toms. Infrequent adverse events were deep vein thrombosis
of the lower leg in 2 (1%) and phlebitis after vinorelbine
infusion in another 2 (1%) patients. Three (1.5%) patients
were hospitalized because of adverse events during or
shortly after chemo-mobilization. One patient developed
neutropenic fever and renal failure after vinorelbine
application, requiring antibiotic treatment, and could not
undergo leukapheresis. One patient had severe bone pain
and was hospitalized the day before successful stem cell
collection for intravenous treatment with opioids. A third
patient was hospitalized 2 days after successful stem cell
collection because of abdominal pain and constipation,Table 5
Risk Factors for CD34þ HPC Collection in Total
Variable Univariate Analysis
Numbers, %/Median
(range)
Median (range
Lenalidomide-containing pretreatment 30/222 (13.5) 5.3 (.6-15-5) v
Thalidomide-containing pretreatment 53/222 (23.9) 6.5 (4-18.3) ve
Age 58.1 (28.8-75.1) -
Male gender 134/223 (60.1) 8.1 (.2-25.9) v
Previous irradiation 18/221 (8) 5.5 (1.7-18.6)
Duration of pretreatment, mo 4 (1-16) -
No. of drugs 3 (0-9) -
No. of lines 1 (0-6) -
Univariate and multiple regression analyses. Correlations coefﬁcient depicted fo
nominal variables together with the corresponding median (range) of the compa
mideecontaining treatment; thalidomide-containing versus no-lenalidomide/no
previous irradiation versus no previous irradiation). P-values < .05 were considerewhich resolved after laxative measures and hydration. Two
patients received transfusion of 2 red blood cell units each
after chemo-mobilization. No thrombocyte unit transfusions
were required.
In 1 patient, the occurrence of a secondary primary
malignancy (stomach cancer) with an additional suspicion of
a myelodysplastic syndrome 4 years after ASCT was
documented.
DISCUSSION
Vinorelbine combined with G-CSF proved to be an
efﬁcacious and safe mobilization regimen in patients with
multiple myeloma. To our knowledge, this is the ﬁrst large-
scale analysis reporting on the usefulness of this regimen
for chemo-mobilization in multiple myeloma patients.
Overall, 95% of the patients could be collected successfully.
An important advantage in comparison to utilizing G-CSF
alone for HPCmobilization is the very reliable harmonization
of the HPC kinetics by priming with vinorelbine. With G-CSF
alone, patients often have to be monitored by daily mea-
surements of CD34þ cell counts in the peripheral blood to
schedule the start of leukaphereses and they have to undergo
multiple leukaphereses of up to 8 consecutive days until the
aspired amount of HPC has been collected [27,28]. In
contrast, 95% of the patients were able to start leukapheresis
as plannedwhen vinorelbinewas administered 8 days before
the anticipated start of the collection, and almost 80% of the
patients could be collected successfully after only 1 leuka-
pheresis. This predictability allowed an optimal schedulingMultiple Regression
) HPC, 106/kg Correlation
Coefﬁcient
P Value Standardized
Regression
Coefﬁcient
Adjusted
P Value
ersus 9.0 (.2-25.9) - <.001 .275 <.001
rsus 9.0 (.2-25.9) - .08 .097 .18
.16 .02 .15 .022
ersus 6.4 (.4-23.8) - .33 - -
versus 7.9 (.2-25.9) - .09 .054 .41
.21 .002 .125 .12
.02 .77 - -
.19 .005 .02 .80
r continuous variables, and median (range) of collected HPC depicted for
rator groups (lenalidomide-containing versus no-lenalidomide/no-thalido-
-thalidomideecontaining treatment; male gender versus female gender;
d statistically signiﬁcant (depicted in bold characters).
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formed and completed during routine working days without
the need of weekend collections. In addition, side effects
were infrequent and well manageable. Overall, 3 patients
were hospitalized during or shortly after chemo-
mobilization because of neutropenic fever with renal fail-
ure, severe bone pain, and painful constipation. Adverse
events most frequently reported were constipation and bone
pain. Although we attribute the former to vinorelbine, the
latter is likely because of daily G-CSF administrations. These
frequently recorded adverse events were easily managed
with the use of laxatives and analgesics. Although peripheral
neurotoxicity is a well-known side effect of vinca-alcaloids,
vinorelbine could be administered quite safely, even in pa-
tients with pre-existing chemotherapy-induced neuropathy.
Only few patients reported an aggravation of their neuro-
logical symptoms. Based on our experience, we consider its
use carefully only in patients with severe neuropathy inter-
fering with activities of daily living. It has to be taken into
account that, due to the retrospective nature of this analysis,
data regarding toxicities are not complete and a reliable
grading was not possible based on the entries in the patient
records.
Only 11 mobilization failures (5%) were observed. These
results compare favorably to the rates reported for chemo-
mobilization with cyclophosphamide plus G-CSF or G-CSF
alone [15,16,29]. Four of these patients received plerixafor
before the second leukapheresis as a salvage strategy, which
resulted in successful HPC collections in 3 of these patients.
Recently, promising data were shown for plerixafor for HPC
mobilization in patients with myeloma with similar success
rates as with our strategy [19]. Considering the high costs of
plerixafor and the efﬁcacy and easy-to-perform nature of the
chemo-mobilization regimenwith vinorelbine plus G-CSF, we
decided to limit the use of plerixafor as salvage strategy for the
few patients with poor CD34þ HPC collection after their ﬁrst
leukapheresis.
The clinical outcome of the patients after ASCT was
excellent and demonstrated that CD34þ cells collected after
chemo-mobilization with vinorelbine plus G-CSF induce
timely hematopoietic recovery.
The duration of the pretreatment as well as the number of
previous treatment regimens were identiﬁed as adverse risk
factors for CD34þ HPC mobilization. A prolonged duration of
pretreatment with potentially cytotoxic drugs, such as alky-
lating agents or immunomodulatory drugs, may have caused
damage to the bone marrow stem cell niche and hampered
successful HPC mobilization [30-32]. However, high-dose
chemotherapy with subsequent autotransplantation is an
established component of the ﬁrst-line treatment of myeloma
patients, and patients proceed to this step usually after 3 to 4
cycles of induction chemotherapy, thus reducing the risk of
mobilization failures.
Patient agewas identiﬁed as another independent negative
factor for HPC mobilization in our analysis. Available data on
the impact of patient age onHPCmobilization are inconclusive
so far [29,33-35]. Aging has been shown to be associated with
reduced bone marrow cellularity, and aged hematopoietic
stem cells show distinct features from young cells, which may
well affect their regenerative potential [36,37]. Thus, advanced
patient age has been incorporated as negative factor into
various mobilization algorithms [35,38,39].
Lenalidomide is more hematotoxic than thalidomide and
may negatively impact HPC collection. Accordingly, pre-
treatment of the patients with lenalidomide proved to be anindependent negative factor for sufﬁcient HPC collection on
the ﬁrst day of leukapheresis and also for the overall
collection success. Furthermore, the amount of HPC collected
after lenalidomide pretreatment was signiﬁcantly lower
compared with the number of HPC collected after thalido-
mide pretreatment. The median amount of CD34þ HPC
collected on the ﬁrst day of leukapheresis in patients who
received lenalidomide before HPC mobilization was below
the required threshold of 4  106 CD34þcells per kg BW,
necessitating additional leukaphereses in these patients. This
result holds true also for the patients who had received only
1 treatment line before collection, ruling out a possible bias
due to more treatment lines in the lenalidomide pretreated
patients. Our data thus conﬁrm other reports of lower
mobilization rates after lenalidomide pretreatment [30,40-
42]. Of note, 5 lenalidomide pretreated patients failed to
mobilize enough HPC, but 2 of these patients could be
salvaged with a second chemo-mobilization of vinorelbine
plus G-CSF. In the literature, mobilization failure rates of up
to 25% have been reported after lenalidomide treatment,
underscoring the efﬁcacy of our regimen even in this high-
risk patient group [41,42]. We also observed, to a lesser
extent compared with lenalidomide, a lower amount of HPC
collected at day 1 after thalidomide pretreatment in the
multivariable analysis, but this difference was not statisti-
cally signiﬁcant for the total collection result. This ﬁnding is
well in line with other reports on the impact of thalidomide
on HPC chemo-mobilization [30,43-45]. However, the
adjusted R-square values for the ﬁnal model were low (.14
and .11, respectively), indicating that the identiﬁed risk fac-
tors are weak predictors.
Given thatmodernmyeloma treatment nowadays does not
incorporate highly hematotoxic compounds during the in-
duction therapy, the outpatient application of vinorelbine
during or shortly after completion of the planned induction
therapy and the collection of HPC after only 1 week is an
optimal and time-sparing strategy that allows prompt transfer
of the patient to the HDT. Furthermore, the high predictability
of this chemo-mobilization regimen makes CD34þ cell moni-
toring in theperipheralbloodduring thecollectionphase in the
majority of cases unnecessary, which increases patients’ com-
fort and results in signiﬁcant time and cost savings.
In conclusion, chemo-mobilization with vinorelbine plus
G-CSF is efﬁcacious and results in successful HPC collections in
95% of the myeloma patients. This regimen is an excellent
alternative to priming with G-CSF alone or combined with
cyclophosphamide with a more favorable toxicity proﬁle,
earlier collection success, and lower costs. Moreover, the
outpatient administration with only 1 single bolus infusion of
vinorelbine and the better timing of leukapheresis enhance
patient comfort and simplify the HPC collection procedure.
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